Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:14 PM
Ignite Modification Date:
2025-12-24 @ 11:14 PM
NCT ID:
NCT00006356
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed recurrent ovarian epithelial cancer after first line chemotherapy, unless clear evidence of clinically progressive disease
* Must have received prior first line chemotherapy consisting of at least 4 courses of either cisplatin or carboplatin
* At least 12 months since prior chemotherapy
* Measurable disease by clinical exam or diagnostic laparoscopy
* At least one lesion greater than 1 cm in diameter
* No leptomeningeal or brain metastases
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* WHO 0-2
Life expectancy:
* Not specified
Hematopoietic:
* Absolute neutrophil count greater than 1,500/mm\^3
* Platelet count greater than 100,000/mm\^3
Hepatic:
* Bilirubin less than 1.25 times upper limit of normal (ULN)
* SGPT less than 2 times ULN
Renal:
* Creatinine less than 1.6 mg/dL OR
* Creatinine clearance greater than 40 mL/min
Other:
* No peripheral neurotoxicity greater than grade 2
* No psychological, familial, sociological, or geographical condition that would preclude study
* No complete bowel obstruction
* No other malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* No more than 1 prior regimen of chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* See Disease Characteristics
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT00006356
Study Brief:
Protocol Section:
NCT00006356